BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Palazestrant readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Palazestrant\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05508906-2666@assetmemo.bio
DTSTAMP:20261121T004554Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Palazestrant: Phase 1 readout est. (NCT05508906)
DESCRIPTION:Palazestrant\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribocic
 lib\, Alpelisib\, Everolimus\, or Atirmociclib in ER+\, HER2- Breast Cance
 r\nEstimated primary completion: 31 December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/palazestrant#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05508906
URL:https://assetmemo.bio/drug/palazestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085767-2666@assetmemo.bio
DTSTAMP:20261121T004554Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Palazestrant: Phase 3 readout est. (NCT07085767)
DESCRIPTION:Palazestrant\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Palazestrant in Combination With Ribociclib for the First-line Treat
 ment of ER+/HER2- Advanced Breast Cancer\nEstimated primary completion: De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palazest
 rant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07085767
URL:https://assetmemo.bio/drug/palazestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
